Katherine E Goodman1, Justin Lessler1, Sara E Cosgrove2, Anthony D Harris3, Ebbing Lautenbach4, Jennifer H Han4, Aaron M Milstone5, Colin J Massey6, Pranita D Tamma5. 1. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health. 2. Department of Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine. 3. Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore. 4. Department of Medicine, Division of Infectious Diseases, University of Pennsylvania School of Medicine, Philadelphia. 5. Department of Pediatrics, Division of Infectious Diseases. 6. Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Abstract
BACKGROUND: Timely identification of extended-spectrum β-lactamase (ESBL) bacteremia can improve clinical outcomes while minimizing unnecessary use of broad-spectrum antibiotics, including carbapenems. However, most clinical microbiology laboratories currently require at least 24 additional hours from the time of microbial genus and species identification to confirm ESBL production. Our objective was to develop a user-friendly decision tree to predict which organisms are ESBL producing, to guide appropriate antibiotic therapy. METHODS: We included patients ≥18 years of age with bacteremia due to Escherichia coli or Klebsiella species from October 2008 to March 2015 at Johns Hopkins Hospital. Isolates with ceftriaxone minimum inhibitory concentrations ≥2 µg/mL underwent ESBL confirmatory testing. Recursive partitioning was used to generate a decision tree to determine the likelihood that a bacteremic patient was infected with an ESBL producer. Discrimination of the original and cross-validated models was evaluated using receiver operating characteristic curves and by calculation of C-statistics. RESULTS: A total of 1288 patients with bacteremia met eligibility criteria. For 194 patients (15%), bacteremia was due to a confirmed ESBL producer. The final classification tree for predicting ESBL-positive bacteremia included 5 predictors: history of ESBL colonization/infection, chronic indwelling vascular hardware, age ≥43 years, recent hospitalization in an ESBL high-burden region, and ≥6 days of antibiotic exposure in the prior 6 months. The decision tree's positive and negative predictive values were 90.8% and 91.9%, respectively. CONCLUSIONS: Our findings suggest that a clinical decision tree can be used to estimate a bacteremic patient's likelihood of infection with ESBL-producing bacteria. Recursive partitioning offers a practical, user-friendly approach for addressing important diagnostic questions.
BACKGROUND: Timely identification of extended-spectrum β-lactamase (ESBL) bacteremia can improve clinical outcomes while minimizing unnecessary use of broad-spectrum antibiotics, including carbapenems. However, most clinical microbiology laboratories currently require at least 24 additional hours from the time of microbial genus and species identification to confirm ESBL production. Our objective was to develop a user-friendly decision tree to predict which organisms are ESBL producing, to guide appropriate antibiotic therapy. METHODS: We included patients ≥18 years of age with bacteremia due to Escherichia coli or Klebsiella species from October 2008 to March 2015 at Johns Hopkins Hospital. Isolates with ceftriaxone minimum inhibitory concentrations ≥2 µg/mL underwent ESBL confirmatory testing. Recursive partitioning was used to generate a decision tree to determine the likelihood that a bacteremic patient was infected with an ESBL producer. Discrimination of the original and cross-validated models was evaluated using receiver operating characteristic curves and by calculation of C-statistics. RESULTS: A total of 1288 patients with bacteremia met eligibility criteria. For 194 patients (15%), bacteremia was due to a confirmed ESBL producer. The final classification tree for predicting ESBL-positive bacteremia included 5 predictors: history of ESBL colonization/infection, chronic indwelling vascular hardware, age ≥43 years, recent hospitalization in an ESBL high-burden region, and ≥6 days of antibiotic exposure in the prior 6 months. The decision tree's positive and negative predictive values were 90.8% and 91.9%, respectively. CONCLUSIONS: Our findings suggest that a clinical decision tree can be used to estimate a bacteremic patient's likelihood of infection with ESBL-producing bacteria. Recursive partitioning offers a practical, user-friendly approach for addressing important diagnostic questions.
Authors: Joshua T Thaden; Vance G Fowler; Daniel J Sexton; Deverick J Anderson Journal: Infect Control Hosp Epidemiol Date: 2015-10-13 Impact factor: 3.254
Authors: David X Li; Anna C Sick-Samuels; Nuntra Suwantarat; Rebecca G Same; Patricia J Simner; Pranita D Tamma Journal: Infect Control Hosp Epidemiol Date: 2017-12-05 Impact factor: 3.254
Authors: M Cristina Vazquez Guillamet; Rodrigo Vazquez; Jonas Noe; Scott T Micek; Victoria J Fraser; Marin H Kollef Journal: Clin Infect Dis Date: 2020-12-15 Impact factor: 9.079
Authors: Mahsa Alizadeh; Ryan L Wood; Clara M Buchanan; Colin G Bledsoe; Madison E Wood; Daniel S McClellan; Rae Blanco; Tanner V Ravsten; Ghaleb A Husseini; Caroline L Hickey; Richard A Robison; William G Pitt Journal: Colloids Surf B Biointerfaces Date: 2017-03-16 Impact factor: 5.268
Authors: Scott L Weiss; Mark J Peters; Waleed Alhazzani; Michael S D Agus; Heidi R Flori; David P Inwald; Simon Nadel; Luregn J Schlapbach; Robert C Tasker; Andrew C Argent; Joe Brierley; Joseph Carcillo; Enitan D Carrol; Christopher L Carroll; Ira M Cheifetz; Karen Choong; Jeffry J Cies; Andrea T Cruz; Daniele De Luca; Akash Deep; Saul N Faust; Claudio Flauzino De Oliveira; Mark W Hall; Paul Ishimine; Etienne Javouhey; Koen F M Joosten; Poonam Joshi; Oliver Karam; Martin C J Kneyber; Joris Lemson; Graeme MacLaren; Nilesh M Mehta; Morten Hylander Møller; Christopher J L Newth; Trung C Nguyen; Akira Nishisaki; Mark E Nunnally; Margaret M Parker; Raina M Paul; Adrienne G Randolph; Suchitra Ranjit; Lewis H Romer; Halden F Scott; Lyvonne N Tume; Judy T Verger; Eric A Williams; Joshua Wolf; Hector R Wong; Jerry J Zimmerman; Niranjan Kissoon; Pierre Tissieres Journal: Intensive Care Med Date: 2020-02 Impact factor: 17.440
Authors: Samuel A Shelburne; Jiwoong Kim; Jose M Munita; Pranoti Sahasrabhojane; Ryan K Shields; Ellen G Press; Xiqi Li; Cesar A Arias; Brandi Cantarel; Ying Jiang; Min S Kim; Samuel L Aitken; David E Greenberg Journal: Clin Infect Dis Date: 2017-09-01 Impact factor: 9.079
Authors: Youn-Jung Kim; Sung Min Jung; Jihoon Kang; Seung Mok Ryoo; Chang Hwan Sohn; Dong-Woo Seo; Kyoung Soo Lim; Jin Won Huh; Sung-Han Kim; Won Young Kim Journal: Intern Emerg Med Date: 2019-01-01 Impact factor: 3.397
Authors: L Surgers; A Boyd; P-Y Boelle; V Lalande; P-A Jolivot; P-M Girard; G Arlet; C Cambier; A Homor; D Decre; J-L Meynard Journal: Eur J Clin Microbiol Infect Dis Date: 2017-02-08 Impact factor: 3.267